Similarly, agonistic activity of tamoxifen increases the proliferation of endometrial cancer cells by activating the GPER-1/EGFR/ERK1/2/CyclinD1 route, data that is in agreement with the observation that endometrial cancer patients under tamoxifen treatment exhibit a worse prognosis (41). Here, GPER1 is linked to endometrial cancer.